EP3290525A4 - Procédé de criblage de médicament et cible thérapeutique utilisée pour le traitement de la maladie d'alzheimer - Google Patents

Procédé de criblage de médicament et cible thérapeutique utilisée pour le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
EP3290525A4
EP3290525A4 EP15890335.1A EP15890335A EP3290525A4 EP 3290525 A4 EP3290525 A4 EP 3290525A4 EP 15890335 A EP15890335 A EP 15890335A EP 3290525 A4 EP3290525 A4 EP 3290525A4
Authority
EP
European Patent Office
Prior art keywords
disease
therapeutic target
treating alzheimer
target used
screening drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15890335.1A
Other languages
German (de)
English (en)
Other versions
EP3290525B1 (fr
EP3290525A1 (fr
Inventor
Fude HUANG
Xiao Zhang
Wenan WANG
Haiyan Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Nuo-Beta Pharmaceutical Technology Co Ltd
Original Assignee
Jiangsu Nuo-Beta Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Nuo-Beta Pharmaceutical Technology Co Ltd filed Critical Jiangsu Nuo-Beta Pharmaceutical Technology Co Ltd
Publication of EP3290525A1 publication Critical patent/EP3290525A1/fr
Publication of EP3290525A4 publication Critical patent/EP3290525A4/fr
Application granted granted Critical
Publication of EP3290525B1 publication Critical patent/EP3290525B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/70—Invertebrates
    • A01K2227/706—Insects, e.g. Drosophila melanogaster, medfly
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0337—Genetically modified Arthropods
    • A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
EP15890335.1A 2015-04-30 2015-04-30 Procédé de criblage de médicament et cible thérapeutique utilisée pour le traitement de la maladie d'alzheimer Active EP3290525B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/078070 WO2016172955A1 (fr) 2015-04-30 2015-04-30 Procédé de criblage de médicament et cible thérapeutique utilisée pour le traitement de la maladie d'alzheimer

Publications (3)

Publication Number Publication Date
EP3290525A1 EP3290525A1 (fr) 2018-03-07
EP3290525A4 true EP3290525A4 (fr) 2018-12-19
EP3290525B1 EP3290525B1 (fr) 2022-02-23

Family

ID=57198995

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15890335.1A Active EP3290525B1 (fr) 2015-04-30 2015-04-30 Procédé de criblage de médicament et cible thérapeutique utilisée pour le traitement de la maladie d'alzheimer

Country Status (9)

Country Link
US (1) US11236378B2 (fr)
EP (1) EP3290525B1 (fr)
JP (1) JP6636614B2 (fr)
KR (3) KR20200011567A (fr)
CN (1) CN107849608A (fr)
AU (1) AU2015392754B2 (fr)
DK (1) DK3290525T3 (fr)
ES (1) ES2913526T3 (fr)
WO (1) WO2016172955A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202126295A (zh) * 2019-09-27 2021-07-16 大陸商江蘇挪貝肽醫藥科技有限公司 一種治療心境障礙的方法
WO2021197389A1 (fr) * 2020-03-31 2021-10-07 挪贝肽医药科技(上海)有限公司 Applications d'inhibiteur de pi4k dans des maladies liées au mauvais repliement de protéines intracellulaires et des maladies de stockage lysosomal
CA3233744A1 (fr) * 2021-09-30 2023-04-06 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Compose d'oxyde de phenylarsine halogene et son utilisation
CN114807114A (zh) * 2022-04-14 2022-07-29 广州医科大学附属第二医院 一种记录果蝇大脑单细胞长时程增强电生理信号的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001772A1 (fr) * 1992-07-13 1994-01-20 The Children's Medical Center Corporation CRIBLAGE DE TRAITEMENTS DE LA MALADIE D'ALZHEIMER SUR LA BASE DE LA PRODUCTION DE β-AMYLOIDE
KR100768381B1 (ko) 1998-09-24 2007-10-18 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
DE19856261C1 (de) * 1998-12-07 2000-03-30 Hoechst Marion Roussel De Gmbh Aß-Peptid Screening Assay
EP1478736A4 (fr) * 2002-02-27 2007-01-10 Pharmacia & Upjohn Co Llc Production de haut niveau de peptides beta-amyloides a partir de cellules imr-32
US20050137142A1 (en) * 2003-11-03 2005-06-23 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP1859274A2 (fr) * 2005-03-07 2007-11-28 Novartis AG Genes associes a des etats neurodegeneratifs
JP2009503027A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病ｉｉの治療のための置換エタン−１，２−ジアミン
CN1907287A (zh) * 2006-08-23 2007-02-07 华东师范大学 β－淀粉样肽抑制剂及其筛选方法
ITMI20071975A1 (it) * 2007-10-12 2009-04-13 Fond I R C C S Istituto Neur O Prodotti e loro uso per la diagnosi prevenzione e-o cura di patologie umane e-o animali caraterizzate dalla anomala deposizione di sostanza b-amiloide e-o similamiloide in organi e tesstui umani e-o animali e metodo di screening per la determinazione
CN102265806B (zh) * 2010-05-13 2013-12-25 中国科学院上海生命科学研究院 抗阿尔茨海默症转基因果蝇模型及其在药物筛选中的应用
CN103529182B (zh) * 2012-07-06 2016-03-16 中国科学院上海生命科学研究院 rbo/Efr3a/Efr3b基因或其蛋白在诊断和治疗阿尔茨海默病中的应用
CN104046676B (zh) * 2013-03-13 2016-03-16 中国科学院上海生命科学研究院 清除淀粉样多肽的细胞及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAVIDE TAMPELLINI ET AL: "Impaired [beta]-amyloid secretion in Alzheimer's disease pathogenesis", THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE, 26 October 2011 (2011-10-26), United States, pages 15384, XP055520453, Retrieved from the Internet <URL:http://www.jneurosci.org/content/jneuro/31/43/15384.full.pdf> [retrieved on 20181031], DOI: 10.1523/JNEUROSCI.2986-11.2011 *
KATJA PRÜSSING ET AL: "Drosophila melanogaster as a model organism for Alzheimer's dis", MOLECULAR NEURODEGENERATION, BIOMED CENTRAL LTD, LO, vol. 8, no. 1, 22 November 2013 (2013-11-22), pages 35, XP021168723, ISSN: 1750-1326, DOI: 10.1186/1750-1326-8-35 *
LIN JING-YA ET AL: "Intraneuronal accumulation of A[beta]42induces age-dependent slowing of neuronal transmission inDrosop", NEUROSCIENCE BULLETIN, SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES, HEIDELBERG, vol. 30, no. 2, 15 April 2014 (2014-04-15), pages 185 - 190, XP035309213, ISSN: 1673-7067, [retrieved on 20140415], DOI: 10.1007/S12264-013-1409-9 *
LOTTA AGHOLME ET AL: "Getting Rid of Intracellular A[beta] . - Loss of Cellular Degradation Leads to Transfer Between Connected Neurons", CURRENT PHARMACEUTICAL DESIGN, vol. 20, no. 15, 12 May 2014 (2014-05-12), NL, pages 2458 - 2468, XP055520447, ISSN: 1381-6128, DOI: 10.2174/13816128113199990501 *
See also references of WO2016172955A1 *

Also Published As

Publication number Publication date
AU2015392754A1 (en) 2017-12-21
EP3290525B1 (fr) 2022-02-23
US11236378B2 (en) 2022-02-01
JP6636614B2 (ja) 2020-01-29
EP3290525A1 (fr) 2018-03-07
AU2015392754B2 (en) 2019-03-14
KR20210035917A (ko) 2021-04-01
ES2913526T3 (es) 2022-06-02
KR20200011567A (ko) 2020-02-03
CN107849608A (zh) 2018-03-27
WO2016172955A1 (fr) 2016-11-03
JP2018520367A (ja) 2018-07-26
DK3290525T3 (da) 2022-03-14
KR20180012274A (ko) 2018-02-05
KR102488987B1 (ko) 2023-01-17
US20190211371A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
EP3347368A4 (fr) Composés et formulations pour traiter les maladies ophthalmiques
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
EP3562514A4 (fr) Thérapie génique pour le traitement de la maladie de wilson
EP3429605A4 (fr) Agent thérapeutique pour le traitement de maladies, notamment les maladies touchant le système nerveux central
EP3294345A4 (fr) Formulations de tpp1 et méthodes de traitement de la maladie cln2
EP3377118A4 (fr) Méthodes pour traiter la maladie d&#39;alzheimer et des troubles associés
EP3268086A4 (fr) Lsd pour le traitement de la maladie d&#39;alzheimer
IL267622A (en) Method for modifying the therapeutic effects of drugs
EP3268007A4 (fr) Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément
EP3192875A4 (fr) Composition pharmaceutique à libération prolongée destinée au traitement et à la prévention de maladies ophtalmiques
EP3664789A4 (fr) Méthodes de traitement de maladies et de lésions des nerfs
EP3318275A4 (fr) Nouvel agent thérapeutique contre les maladies pulmonaires et/ou méthode de criblage de ces dernières
EP3347486A4 (fr) Réduction du fragment c99 de l&#39;app localisé sur la membrane er-mam et procédés de traitement de la maladie d&#39;alzheimer
EP3650860A4 (fr) Médicament thérapeutique pour maladies induites par une peroxydation lipidique et procédé de criblage pour des médicaments thérapeutiques pour des maladies induites par une peroxydation lipidique
EP3290525A4 (fr) Procédé de criblage de médicament et cible thérapeutique utilisée pour le traitement de la maladie d&#39;alzheimer
EP3310377A4 (fr) Méthode de traitement de la maladie de crohn
EP3375443A4 (fr) Composition pharmaceutique indiquée pour le traitement de maladies liées au système respiratoire
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
EP3398614A4 (fr) Agent pour la prévention et/ou le traitement de la maladie d&#39;alzheimer
EP3429569A4 (fr) Méthodes destinées à prévenir ou à traiter la maladie de parkinson par farnésylation de paris
EP3283457A4 (fr) Composés et procédés pour le traitement de maladies neurodégénératives
EP3162377A4 (fr) Utilisation d&#39;alpha-asarone dans la préparation de médicaments pour prévenir et traiter la maladie d&#39;alzheimer
EP3538095A4 (fr) Méthode de traitement de la maladie de parkinson
EP3402778A4 (fr) Procédés et compositions médicamenteuses destinés au traitement de la maladie de lyme
EP3310310A4 (fr) Appareil pour le traitement de la maladie de ménière

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015077167

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12Q0001680000

Ipc: G01N0033530000

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101AFI20181107BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20181115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200323

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210916

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015077167

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20220309

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1470859

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2913526

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220602

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1470859

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220623

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220523

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220524

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015077167

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220430

26N No opposition filed

Effective date: 20221124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220430

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230427

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230427

Year of fee payment: 9

Ref country code: FR

Payment date: 20230428

Year of fee payment: 9

Ref country code: ES

Payment date: 20230517

Year of fee payment: 9

Ref country code: DK

Payment date: 20230427

Year of fee payment: 9

Ref country code: DE

Payment date: 20230517

Year of fee payment: 9

Ref country code: CH

Payment date: 20230602

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20230427

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230515

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20150430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223